Delcath Systems (NASDAQ:DCTH – Get Free Report) released its earnings results on Tuesday. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.19, RTT News reports. The company had revenue of $0.54 million during the quarter, compared to analyst estimates of $0.48 million. Delcath Systems had a negative return on equity of 1,007.65% and a negative net margin of 2,308.86%. During the same period in the prior year, the company posted ($0.86) earnings per share.
Delcath Systems Price Performance
Shares of DCTH opened at $5.09 on Thursday. The company has a quick ratio of 3.11, a current ratio of 3.30 and a debt-to-equity ratio of 0.08. The firm’s 50 day simple moving average is $4.34 and its 200 day simple moving average is $3.84. Delcath Systems has a 1-year low of $2.25 and a 1-year high of $7.99.
Insider Activity
In other news, Director Gil Aharon bought 26,882 shares of the company’s stock in a transaction dated Tuesday, March 19th. The stock was bought at an average cost of $3.72 per share, for a total transaction of $100,001.04. Following the completion of the acquisition, the director now owns 1,069,710 shares in the company, valued at approximately $3,979,321.20. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 21.10% of the company’s stock.
Institutional Trading of Delcath Systems
Wall Street Analysts Forecast Growth
DCTH has been the subject of several research analyst reports. StockNews.com raised Delcath Systems to a “sell” rating in a research report on Wednesday. HC Wainwright lifted their price target on shares of Delcath Systems from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to data from MarketBeat.com, Delcath Systems presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.50.
Read Our Latest Report on DCTH
About Delcath Systems
Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Read More
- Five stocks we like better than Delcath Systems
- Stock Dividend Cuts Happen Are You Ready?
- Krispy Kreme’s Sweet Deal: McDonald’s Partnership Sparks Growth?
- Best Aerospace Stocks Investing
- Bitcoin Depot Falls Into Value Territory With Expansion Underway
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- 7 Stocks That Will Drive the Weight Loss Drugs Market
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.